The importance of proteogenomics in drug discovery

The latest DDW Sitting Down With podcast features Anders Mälarstig, Director of Human Genetics, Pfizer. In this podcast he outlines the role of pQTLs in the drug discovery process and the growing importance of proteogenomics

Mälarstig  is currently responsible for developing and applying strategies for new drug targets and precision medicine. He has extensive experience working in international academic consortia and public–private partnerships such as the SCALLOP consortium.

Listen to this podcast to hear Mälarstig  discuss proteogenomics, an emerging approach that aims to advance basic, translational and clinical research. He will also explain why the drug discovery sector should take an interest in it, what insights it can provide to researchers and the opportunities it is creating for drug discovery companies.

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free